United States Pharmaceuticals

Novan Inc (NOVN)

Track

Track

Novan Inc. has not recorded any insider trading activity within the last three months. The most recent transactions occurred in June 2023, involving sales by Machelle Sanders and John M. Gay. Prior to these disposals, historical records show various purchase activities by company leadership dating back to 2022.
Ticker: NOVN Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Novan Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.2
SANDERS MACHELLE Non-Executive Director
Transaction date
Sale
Price
73.82
Quantity 82,653 +3.4%
Value US$4,263,677
3.6
GAY JOHN M. Officer Officer
Transaction date
Proposed sale
Price
460.44
Quantity 37,844
Value US$2,459,290
1.1
BIERMAN JAMES L Non-Executive Director
Transaction date
Purchase
Price
388.38
Quantity 73,971 +9.2%
Value US$108,195
1.1
BIERMAN JAMES L Non-Executive Director
Transaction date
Purchase
Price
3.45
Quantity 1,000 +50.0%
Value US$3,450
1.1
BIERMAN JAMES L Non-Executive Director
Transaction date
Purchase
Price
3.55
Quantity 2,000 +inf%
Value US$7,090
3.6
GAY JOHN M. Chief Financial Officer Officer
Transaction date
Purchase
Price
3.50
Quantity 1,000 +66.7%
Value US$3,500
2.8
PALMOUR JOHN W Non-Executive Director
Transaction date
Purchase
Price
3.64
Quantity 10,000 +16.8%
Value US$36,350
2.8
PALMOUR JOHN W Non-Executive Director
Transaction date
Purchase
Price
3.34
Quantity 5,000 +9.2%
Value US$16,705
2.8
PALMOUR JOHN W Non-Executive Director
Transaction date
Purchase
Price
3.34
Quantity 5,000 +10.1%
Value US$16,685
3.1
STAFFORD PAULA B President and CEO Executive Director
Transaction date
Purchase
Price
1.43
Quantity 70,000 +86.7%
Value US$100,100
2.8
PALMOUR JOHN W Non-Executive Director
Transaction date
Purchase
Price
0.00
Quantity 200,000
Value US$0
2.2
SANDERS MACHELLE Non-Executive Director
Transaction date
Purchase
Price
0.00
Quantity 7,000
Value US$0
3.7
Martin G. Kelly Chief Executive Officer Executive Director
Transaction date
Purchase
Price
1.97
Quantity 1,500 +3.4%
Value US$2,955
3.7
Martin G. Kelly Chief Executive Officer Executive Director
Transaction date
Purchase
Price
2.15
Quantity 3,500 +8.8%
Value US$7,525
2.8
PALMOUR JOHN W Non-Executive Director
Transaction date
Purchase
Price
2.20
Quantity 20,000 +7.3%
Value US$44,000
3.1
INGRAM ROBERT ALEXANDER Non-Executive Director
Transaction date
Purchase
Price
2.21
Quantity 50,000 +41.7%
Value US$110,500
3.3
Geer W Kent
Transaction date
Purchase
Price
1.90
Quantity 5,000 +46.2%
Value US$9,500
3.1
STAFFORD PAULA B President and COO Executive Director
Transaction date
Purchase
Price
1.92
Quantity 80,000 +11544.0%
Value US$153,600
3.7
Martin G. Kelly Chief Executive Officer Executive Director
Transaction date
Purchase
Price
1.43
Quantity 40,000 +inf%
Value US$57,200
3.7
Martin G. Kelly Chief Executive Officer Executive Director
Transaction date
Purchase
Price
1.43
Quantity 20,000 +50.0%
Value US$28,600
3.6
GAY JOHN M. VP, Finance & Corp. Controller
Transaction date
Purchase
Price
1.50
Quantity 14,900 +14900.0%
Value US$22,350
3.4
NOVAK ANDREW VP, Accounting and Bus Ops
Transaction date
Purchase
Price
1.47
Quantity 5,400 +415.4%
Value US$7,938
3.1
STAFFORD PAULA B President and COO Executive Director
Transaction date
Purchase
Price
1.49
Quantity 693 +inf%
Value US$1,033
INGRAM ROBERT ALEXANDER Non-Executive Director
Transaction date
Purchase
Price
2.84
Quantity 50,000 +71.7%
Value US$142,000
Martin G. Kelly Chief Executive Officer Executive Director
Transaction date
Purchase
Price
2.73
Quantity 10,000 +33.3%
Value US$27,300
2.8
PALMOUR JOHN W Non-Executive Director
Transaction date
Purchase
Price
2.66
Quantity 20,000 +7.9%
Value US$53,200
Martin G. Kelly Chief Executive Officer Executive Director
Transaction date
Purchase
Price
2.71
Quantity 30,000 +inf%
Value US$81,300
INGRAM ROBERT ALEXANDER
Transaction date
Purchase
Price
4.70
Quantity 8,465 +13.8%
Value US$39,786
INGRAM ROBERT ALEXANDER
Transaction date
Purchase
Price
4.25
Quantity 3,535 +6.1%
Value US$15,024
2.8
PALMOUR JOHN W
Transaction date
Purchase
Price
3.99
Quantity 12,000 +5.0%
Value US$47,880
Malin Life Sciences Holdings Ltd Large shareholder
Transaction date
Purchase
Price
11.00
Quantity 800,000 +43.9%
Value US$8,800,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-06-27 2023-06-27 S Sale
2.2
SANDERS MACHELLE
Non-Executive Director
82,653 +3.4%
73.82
US$4,263,677 		82,653 +3.4% 73.82 US$4,263,677
2023-06-09 2023-06-09 PrS Proposed sale
3.6
GAY JOHN M.

Officer

Officer
37,844
460.44
US$2,459,290 		37,844 460.44 US$2,459,290
2022-04-11 2022-04-07 B Purchase
1.1
BIERMAN JAMES L
Non-Executive Director
73,971 +9.2%
388.38
US$108,195 		73,971 +9.2% 388.38 US$108,195
2022-03-30 2022-03-28 B Purchase
1.1
BIERMAN JAMES L
Non-Executive Director
1,000 +50.0%
3.45
US$3,450 		1,000 +50.0% 3.45 US$3,450
2022-03-28 2022-03-25 B Purchase
1.1
BIERMAN JAMES L
Non-Executive Director
2,000 +inf%
3.55
US$7,090 		2,000 +inf% 3.55 US$7,090
2022-03-22 2022-03-18 B Purchase
3.6
GAY JOHN M.

Chief Financial Officer

Officer
1,000 +66.7%
3.50
US$3,500 		1,000 +66.7% 3.50 US$3,500
2022-03-22 2022-03-18 B Purchase
2.8
PALMOUR JOHN W
Non-Executive Director
10,000 +16.8%
3.64
US$36,350 		10,000 +16.8% 3.64 US$36,350
2022-03-18 2022-03-17 B Purchase
2.8
PALMOUR JOHN W
Non-Executive Director
5,000 +9.2%
3.34
US$16,705 		5,000 +9.2% 3.34 US$16,705
2022-03-18 2022-03-16 B Purchase
2.8
PALMOUR JOHN W
Non-Executive Director
5,000 +10.1%
3.34
US$16,685 		5,000 +10.1% 3.34 US$16,685
2021-03-29 2021-03-26 B Purchase
3.1
STAFFORD PAULA B

President and CEO

Executive Director
70,000 +86.7%
1.43
US$100,100 		70,000 +86.7% 1.43 US$100,100
2020-03-05 2020-03-03 B Purchase
2.8
PALMOUR JOHN W
Non-Executive Director
200,000
0.00
US$0 		200,000 0.00 US$0
2020-03-05 2020-03-03 B Purchase
2.2
SANDERS MACHELLE
Non-Executive Director
7,000
0.00
US$0 		7,000 0.00 US$0
2019-07-02 2019-07-02 S Sale
3.3
Malin Life Sciences Holdings Ltd
Large shareholder
6,287 -0.2%
2.75
US$17,289 		6,287 -0.2% 2.75 US$17,289
2019-07-02 2019-07-01 S Sale
3.3
Malin Life Sciences Holdings Ltd
Large shareholder
913 -0.0%
2.74
US$2,502 		913 -0.0% 2.74 US$2,502
2019-07-02 2019-06-28 S Sale
3.3
Malin Life Sciences Holdings Ltd
Large shareholder
17,800 -0.7%
2.69
US$47,882 		17,800 -0.7% 2.69 US$47,882
2019-05-30 2019-05-29 B Purchase
3.7
Martin G. Kelly

Chief Executive Officer

Executive Director
1,500 +3.4%
1.97
US$2,955 		1,500 +3.4% 1.97 US$2,955
2019-05-29 2019-05-28 B Purchase
3.7
Martin G. Kelly

Chief Executive Officer

Executive Director
3,500 +8.8%
2.15
US$7,525 		3,500 +8.8% 2.15 US$7,525
2019-05-29 2019-05-24 B Purchase
2.8
PALMOUR JOHN W
Non-Executive Director
20,000 +7.3%
2.20
US$44,000 		20,000 +7.3% 2.20 US$44,000
2019-05-23 2019-05-22 B Purchase
3.1
INGRAM ROBERT ALEXANDER
Non-Executive Director
50,000 +41.7%
2.21
US$110,500 		50,000 +41.7% 2.21 US$110,500
2019-05-23 2019-05-21 B Purchase
3.3
Geer W Kent
5,000 +46.2%
1.90
US$9,500 		5,000 +46.2% 1.90 US$9,500
2019-05-21 2019-05-20 B Purchase
3.1
STAFFORD PAULA B

President and COO

Executive Director
80,000 +11544.0%
1.92
US$153,600 		80,000 +11544.0% 1.92 US$153,600
2019-05-21 2019-05-17 B Purchase
3.7
Martin G. Kelly

Chief Executive Officer

Executive Director
40,000 +inf%
1.43
US$57,200 		40,000 +inf% 1.43 US$57,200
2019-05-21 2019-05-17 B Purchase
3.7
Martin G. Kelly

Chief Executive Officer

Executive Director
20,000 +50.0%
1.43
US$28,600 		20,000 +50.0% 1.43 US$28,600
2019-05-21 2019-05-17 B Purchase
3.6
GAY JOHN M.

VP, Finance & Corp. Controller
14,900 +14900.0%
1.50
US$22,350 		14,900 +14900.0% 1.50 US$22,350
2019-05-21 2019-05-17 B Purchase
3.4
NOVAK ANDREW

VP, Accounting and Bus Ops
5,400 +415.4%
1.47
US$7,938 		5,400 +415.4% 1.47 US$7,938
2019-05-21 2019-05-17 B Purchase
3.1
STAFFORD PAULA B

President and COO

Executive Director
693 +inf%
1.49
US$1,033 		693 +inf% 1.49 US$1,033
2018-10-01 2018-09-28 B Purchase INGRAM ROBERT ALEXANDER Non-Executive Director
50,000 +71.7%
2.84
US$142,000 		50,000 +71.7% 2.84 US$142,000
2018-09-27 2018-09-26 B Purchase Martin G. Kelly

Chief Executive Officer

Executive Director
10,000 +33.3%
2.73
US$27,300 		10,000 +33.3% 2.73 US$27,300
2018-08-24 2018-08-22 B Purchase
2.8
PALMOUR JOHN W
Non-Executive Director
20,000 +7.9%
2.66
US$53,200 		20,000 +7.9% 2.66 US$53,200
2018-08-23 2018-08-21 B Purchase Martin G. Kelly

Chief Executive Officer

Executive Director
30,000 +inf%
2.71
US$81,300 		30,000 +inf% 2.71 US$81,300
2017-08-29 2017-08-29 B Purchase INGRAM ROBERT ALEXANDER
8,465 +13.8%
4.70
US$39,786 		8,465 +13.8% 4.70 US$39,786
2017-08-29 2017-08-25 B Purchase INGRAM ROBERT ALEXANDER
3,535 +6.1%
4.25
US$15,024 		3,535 +6.1% 4.25 US$15,024
2017-08-25 2017-08-23 B Purchase
2.8
PALMOUR JOHN W
12,000 +5.0%
3.99
US$47,880 		12,000 +5.0% 3.99 US$47,880
2016-09-28 2016-09-26 B Purchase Malin Life Sciences Holdings Ltd Large shareholder
800,000 +43.9%
11.00
US$8,800,000 		800,000 +43.9% 11.00 US$8,800,000
Explore more

More insider trading research around Novan Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America